Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websitenovo.dk/composite...
Phone+45 88 24 88 24
Employees

Funds

Offices

Bagsvaerd, DNK
Krogshoejvej 41
Bagsvaerd, DK-2880, DNK
USA Visiting address
Novo Ventures (US) Inc. 1700 Owens Street, Suite 540
San Francisco, CA, 94158
USA

People

Managing Partner
Managing Partner, Large Investments
Partner & Investment Manager
Partner
Partner
Partner
Partner
Partner
Show All People

Tags

Novo Ventures

Novo A/S is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, and the holding company of the Novo Group and as such the majority shareholder in the publicly listed companies Novo Nordisk A/S and Novozymes A/S.

Novo A/S was established in 1999 prior to the demerger of Novo Nordisk A/S, where Novozymes A/S was established as a stand-alone publicly listed company. Novo’s purpose and objectives are to manage the Foundation’s financial assets and to ensure the Foundation sufficient dividends to cover its grant obligations for medical and scientific research etc. in Scandinavia.

Novo A/S attains these objectives through: compliance with the rules and principles which are set out in the Articles of Association of the Novo Nordisk Foundation regarding exercise of the voting rights of A and B shares in Novo Nordisk A/S and Novozymes A/S, respectively, assurance that all companies in which the company has a material influence actively contribute to the development of the Novo Group and operate their business in accordance with the visions and values of the Novo Group, maintenance of a material influence on Novo Nordisk A/S and Novozymes A/S, and investment and financing business including placing of capital in companies and real property domestically and abroad.

Novo’s overall investment strategy is thus to maintain ownership of Novo Nordisk’ and Novozymes’ shares at a level just above 25% and to invest dividends from these companies and other income in the life science area as well as in a broad portfolio of financial assets.

Novo A/S has since 1999 established itself as an international venture capital partner in the life science area and has invested in over 50 companies in Denmark, Europe and North America.

Through its financial investment activities Novo A/S seeks to spread the company’s total financial risk and at the same time to ensure a high return taking into consideration the chosen risk profile.

In 2007 Novo A/S together with the Novo Nordisk Foundation established ‘Novo Seeds’. The new program (split into two sub-programs) is aimed at supporting early stage applied research in the life science area in Scandinavia.

At the beginning of 2009 Novo A/S launched a new initiative, investing ‘growth equity’ into promising later stage/commercial stage life science companies.

Novo A/S represents the interests of the Novo Nordisk Foundation through participation on the boards of the companies in the Novo Group.

The companies in the Novo Group are members of a ‘family of companies’, independently managed, but sharing a set of common values as set out in the ‘Charter for Companies in the Novo Group’. In the Charter these core values, commitments and management principles that companies in the Novo Group should live up to are described.

Recent Milestones

Investments

Company Date Round Size Participants
PanOptica 4/2014Series B$45M3
Alios BioPharma 4/2014Series B$41M4
Thesan Pharmaceuticals 2/2014Series B$49M4
Otonomy 9/2013Series C$45.9M8
Nevro 3/2013Series C$48M9
Ceterix Orthopaedics 1/2013Series B$19.5M3
Thesan Pharmaceuticals 10/2012Series A$16M2
Alder Biopharmaceuticals 4/2012Series D$38M7
Elevation Pharmaceuticals 1/2012Series B$30M5
Imagen Biotech 10/2011Series A$40M3
Delenex Therapeutics 5/2011Series A$19.3M6
f-star Biotech 4/2011Venture Round€15M7
Otonomy 8/2010Series B$38.5M4
Foldrx Pharmaceuticals 6/2010Venture Round$29M7
Funxional Therapeutics 5/2010Series B$12.2M3
NeuroTherapeutics Pharma 5/2010Series B$43M4
Neomend 1/2010Series D$30M5
Tarsa Therapeutics 1/2010Series A$24M3
CymaBay Therapeutics 11/2009Venture Round$8.6M12
Gloucester Pharmaceuticals 8/2009Series D$29M5
MediQuest Therapeutics 6/2009Series B$23M4
Alios BioPharma 6/2009Series A$8M3
Alios BioPharma 2/2009Series A$24M3
Synosia Therapeutics 1/2009Series B$29M7
CymaBay Therapeutics 4/2007Series D$32M16
CellBiosciences 1/2006Series B$27M8

Videos

Sources

  1. PanOptica Closes Up To $45M in Series B Funding (finsmes.com) [edit]
  2. Alios BioPharma Completes $41M Series B Financing (finsmes.com) [edit]
  3. Thesan Pharmaceuticals Closes $49M Series B Financing (finsmes.com) [edit]
  4. Otonomy completes $45.9m Series C financing (finsmes.com) [edit]
  5. Nevro Raises $48M in Series C Financing (finsmes.com) [edit]
  6. Ceterix Orthopaedics Raises $19.5M in Series B Financing (finsmes.com) [edit]
  7. Thesan Pharmaceuticals Closes $16M Series A Financing (finsmes.com) [edit]
  8. Alder BioPharmaceuticals Inc. Closes $38 Million Series D Financing to Accelerate Clinical Development of its Pipeline of Antibody Therapeutics (prnewswire.com) [edit]
  9. Elevation Pharmaceuticals Completes $30 Million Series B Financing to Advance Aerosol COPD Therapy (elevationpharma.com) [edit]
  10. Imagen Biotech Secures Up to $40 Million to Advance Ophthalmology Therapies (businesswire.com) [edit]
  11. Delenex Therapeutics Raises $19.3M (finsmes.com) [edit]
  12. f-star raises €15M in a New Financing led by SR One (f-star.com) [edit]
  13. Otonomy Closes $38.5 Million Series B Financing (otonomy.com) [edit]
  14. FoldRx banks $29M for neurodegenerative drug application (fiercebiotech.com) [edit]
  15. Funxional Therapeutics, Ltd.: Series B $12.2M (onbiovc.com) [edit]
  16. Big Pharma firms back $43M round for NeuroTherapeutics (fiercebiotech.com) [edit]
  17. Neomend Closes $30M Funding Round (finsmes.com) [edit]
  18. Tarsa Therapeutics, Inc.: Series A $24M (onbiovc.com) [edit]
  19. Metabolex (Metabolex.com) [edit]
  20. Gloucester Pharmaceuticals Completes $29 Million Financing (gloucesterpharma.com) [edit]
  21. MediQuest Therapeutics, Inc.: Series B $23M (onbiovc.com) [edit]
  22. Alios raises another $8M (fiercebiotech.com) [edit]
  23. Alios BioPharma, Inc. Completes First Closing of Series A Financing with Commitment of $24 MM from 3 (aliosbiopharma.com) [edit]
  24. Synosia raises $29M for Phase II testing (fiercebiotech.com) [edit]
  25. Metabolex (Metabolex.com) [edit]
  26. Bio-Medicine (bio-medicine.org) [edit]
Edit This Page
Last Edited 4/15/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy